Background: For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans.
Objective: This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans.
Methods: Baseline blood work and vital signs were obtained from 2 participants before and after each infusion. On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 2, fasting blood work was repeated, vital signs were recorded, and 20 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day 3, fasting blood work and vital signs were repeated. Patients were questioned about any side effects at each appointment.
Setting: This study was performed at a private clinic in Florida.
Participants: Two patients participated: a 58-year-old Asian male and a 68-year-old Caucasian female, each of whom had received intravenous BPC-157 before this trial.
Results: The infusions of BPC-157 resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. The BPC-157 peptide infusion was tolerated, with no side effects reported.
Conclusion: Intravenous infusion of up to 20 mg of BPC-157 in 2 healthy adults showed no adverse effects and was well-tolerated. The results of this pilot study showed the safety of BPC-157 in humans. Future studies are also needed to confirm the safety of intravenous BPC-157 in humans.